Filing Flows › Tandem Diabetes Care (TNDM) › Q2 2025
Tandem Diabetes Care (TNDM) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Tandem Diabetes Care (TNDM) reported revenue of $241M for the second quarter 2025 (Q2 2025), +8% from a year earlier and +3% from the quarter before. Operating margin was -21.5%, net loss $52.4M (21.8% of revenue).
Tandem Diabetes Care, Q2 2025: revenue $241M (+8% year over year), operating margin -21.5%, net loss $52.4M, operating cash flow −$9.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $241M | +3% | +8% |
| Operating profit | −$51.8M | — | — |
| Net earnings | −$52.4M | — | — |
| Operating cash flow | −$9.5M | — | — |
What changed
Revenue was $240.7M in Q2 2025, up 8% year over year and up 3% from the previous quarter. Supplies and other was the largest line at 54% of revenue. Supplies and other added $14.9M year over year (up 13%), 80% of the total change.
Gross margin was 52.3%, up 1.5 points from a year earlier. Operating costs exceeded revenue by $51.8M, an operating margin of -21.5%. Operating expenses grew 24% against revenue growth of 8%. The fastest-growing cost line was SG&A (+16%). The quarter ended with a net loss of $52.4M, narrower than the previous quarter's $130.6M loss.
Operating cash flow was −$9.5M. Non-cash charges added back $4.4M of depreciation and amortization and $25.6M of share-based compensation. Working capital and other items added $12.9M. Capital expenditures of $6.2M exceeded it, leaving free cash flow of −$15.7M.
Questions
What was Tandem Diabetes Care's revenue in the second quarter 2025?
Tandem Diabetes Care (TNDM) reported revenue of $241M for the second quarter 2025 (Q2 2025), +8% from a year earlier and +3% from the quarter before.
Was Tandem Diabetes Care profitable in the second quarter 2025?
Operating loss was $51.8M (-21.5% of revenue) and net loss $52.4M.